Having showcased its pipeline at an R&D day, Novartis AG has also unveiled ambitious plans to expand its biggest-selling drug Cosentyx from its three already-approved indications to ten over the next ten years.
Speaking to Scrip before the London event on 5 December, John Tsai, head of global drug development and chief medical officer, said that the immunology drug had proved hugely successful for psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS)